Kyu-Man Han

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3344876/publications.pdf

Version: 2024-02-01

116194 139680 5,188 185 36 61 citations g-index h-index papers 190 190 190 7690 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Decreased cortical gyrification in patients with bipolar disorder. Psychological Medicine, 2022, 52, 2232-2244.	2.7	9
2	Association of Depression With Atrial Fibrillation in South Korean Adults. JAMA Network Open, 2022, 5, e2141772.	2.8	16
3	Pharmacotherapy for late-life depression. Journal of the Korean Medical Association, 2022, 65, 176-184.	0.1	0
4	The Indirect Effect of Prefrontal Gray Matter Volume on Suicide Attempts among Individuals with Major Depressive Disorder. Experimental Neurobiology, 2022, 31, 97-104.	0.7	3
5	Gender discrimination in workplace and depressive symptoms in female employees in South Korea. Journal of Affective Disorders, 2022, 306, 269-275.	2.0	8
6	Associations between cognitive impairment and cortical thickness alterations in patients with euthymic and depressive bipolar disorder. Psychiatry Research - Neuroimaging, 2022, 322, 111462.	0.9	0
7	Association between work-family conflict and depressive symptoms in female workers: An exploration of potential moderators. Journal of Psychiatric Research, 2022, 151, 113-121.	1.5	12
8	Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study. Psychiatry Investigation, 2022, 19, 268-280.	0.7	5
9	Association of DNA Methylation of the NLRP3 Gene with Changes in Cortical Thickness in Major Depressive Disorder. International Journal of Molecular Sciences, 2022, 23, 5768.	1.8	4
10	Neural substrates for late-life depression: A selective review of structural neuroimaging studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110010.	2.5	37
11	Cerebral amyloid accumulation is associated with distinct structural and functional alterations in the brain of depressed elders with mild cognitive impairment. Journal of Affective Disorders, 2021, 281, 459-466.	2.0	14
12	Social participation and depressive symptoms in community-dwelling older adults: Emotional social support as a mediator. Journal of Psychiatric Research, 2021, 137, 589-596.	1.5	68
13	Development of Neuroimaging-Based Biomarkers in Major Depression. Advances in Experimental Medicine and Biology, 2021, 1305, 85-99.	0.8	8
14	How Inflammation Affects the Brain in Depression: A Review of Functional and Structural MRI Studies.		

#	Article	IF	CITATIONS
19	Long working hours and depressive symptoms: moderation by gender, income, and job status. Journal of Affective Disorders, 2021, 286, 99-107.	2.0	16
20	Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder. Clinical Psychopharmacology and Neuroscience, 2021, 19, 243-253.	0.9	4
21	Association of Prefrontal Cortex Thinning with High Impulsivity in Healthy Adults. Psychiatry Investigation, 2021, 18, 570-579.	0.7	9
22	Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?. Clinical Psychopharmacology and Neuroscience, 2021, 19, 434-448.	0.9	7
23	Changes in Brain Electrical Activity According to Post-traumatic Stress Symptoms in Survivors of the Sewol Ferry Disaster: A 1-year Longitudinal Study. Clinical Psychopharmacology and Neuroscience, 2021, 19, 537-544.	0.9	2
24	Association between high-sensitivity C-reactive protein levels and depression: Moderation by age, sex, obesity, and aerobic physical activity. Journal of Affective Disorders, 2021, 291, 375-383.	2.0	10
25	Cortical Thickness and Surface Area Abnormalities in Bipolar I and II Disorders. Psychiatry Investigation, 2021, 18, 850-863.	0.7	6
26	Prospective study on microstructure in medication-na \tilde{A} -ve adolescents with first-episode major depressive disorder. Journal of Affective Disorders, 2021, 293, 268-275.	2.0	5
27	Brain amyloid accumulation possibly exacerbates concurrent mild cognitive impairment with subthreshold depression in older adults: A 1-year follow-up study. Journal of Affective Disorders, 2021, 295, 93-100.	2.0	2
28	Volumetric alterations in subregions of the amygdala in adults with major depressive disorder. Journal of Affective Disorders, 2021, 295, 108-115.	2.0	12
29	Alterations in the Occipital Cortex of Drug-NaÃ-ve Adults With Major Depressive Disorder: A Surface-Based Analysis of Surface Area and Cortical Thickness. Psychiatry Investigation, 2021, 18, 1025-1033.	0.7	10
30	Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia. Clinical Psychopharmacology and Neuroscience, 2021, 19, 600-609.	0.9	6
31	The neural circuit model of depression and the therapeutic mechanism of cognitive behavioral therapy: A review of functional brain magnetic resonance imaging studies. Cognitive Behavior Therapy in Korea, 2021, 21, 665-688.	0.1	1
32	Alterations in functional brain networks in depressed patients with a suicide attempt history. Neuropsychopharmacology, 2020, 45, 964-974.	2.8	22
33	Pathways to care for people with dementia: An international multicentre study. International Journal of Geriatric Psychiatry, 2020, 35, 163-173.	1.3	15
34	Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 901-910.	1.8	8
35	Elevation of plasma soluble amyloid precursor protein beta in Alzheimer's disease. Archives of Gerontology and Geriatrics, 2020, 87, 103995.	1.4	12
36	A study combining whole-exome sequencing and structural neuroimaging analysis for major depressive disorder. Journal of Affective Disorders, 2020, 262, 31-39.	2.0	10

#	Article	IF	CITATIONS
37	Validation of the Korean version of the Generalized Anxiety Disorder 7 selfâ€rating Scale. Asia-Pacific Psychiatry, 2020, , e12421.	1.2	25
38	Local shape volume alterations in subcortical structures of suicide attempters with major depressive disorder. Human Brain Mapping, 2020, 41, 4925-4934.	1.9	7
39	<p>Definition and Identification of Patients with Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2929-2941.	1.0	7
40	<p>Management of Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2943-2959.	1.0	5
41	Normative data and psychometric properties of the Patient Health Questionnaire-9 in a nationally representative Korean population. BMC Psychiatry, 2020, 20, 194.	1.1	33
42	Changes in cortical thickness and volume of cerebellar subregions in patients with bipolar disorders. Journal of Affective Disorders, 2020, 271, 74-80.	2.0	3
43	Comparative efficacy and acceptability of pharmacological interventions for the treatment and prevention of delirium: A systematic review and network meta-analysis. Journal of Psychiatric Research, 2020, 125, 164-176.	1.5	33
44	Comparison of shape alterations of the thalamus and caudate nucleus between drug-naÃ-ve major depressive disorder patients and healthy controls. Journal of Affective Disorders, 2020, 264, 279-285.	2.0	9
45	Association between weekend catch-up sleep and high-sensitivity C-reactive protein levels in adults: a population-based study. Sleep, 2020, 43, .	0.6	17
46	Serum FAM19A5 levels: A novel biomarker for neuroinflammation and neurodegeneration in major depressive disorder. Brain, Behavior, and Immunity, 2020, 87, 852-859.	2.0	27
47	Emotional Changes and Protective Factors of Emotional Workers in the Public and Private Sector. Psychiatry Investigation, 2020, 17, 645-653.	0.7	4
48	Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. Clinical Psychopharmacology and Neuroscience, 2020, 18, 153-158.	0.9	9
49	<i>ZNF804A</i> Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders. Clinical Psychopharmacology and Neuroscience, 2020, 18, 231-240.	0.9	5
50	Increased plasma complement factor H is associated with geriatric depression. International Psychogeriatrics, 2019, 31, 101-108.	0.6	15
51	Chronic medical conditions and metabolic syndrome as risk factors for incidence of major depressive disorder: A longitudinal study based on 4.7 million adults in South Korea. Journal of Affective Disorders, 2019, 257, 486-494.	2.0	31
52	Effect of physical activity on suicidal ideation differs by gender and activity level. Journal of Affective Disorders, 2019, 257, 116-122.	2.0	8
53	Association between brain amyloid accumulation and neuropsychological characteristics in elders with depression and mild cognitive impairment. International Journal of Geriatric Psychiatry, 2019, 34, 1907-1915.	1.3	10
54	ARPNet: Antidepressant Response Prediction Network for Major Depressive Disorder. Genes, 2019, 10, 907.	1.0	23

#	Article	IF	CITATIONS
55	Usefulness of the 15-item geriatric depression scale (GDS-15) for classifying minor and major depressive disorders among community-dwelling elders. Journal of Affective Disorders, 2019, 259, 370-375.	2.0	70
56	Comparison of the Usefulness of the PHQ-8 and PHQ-9 for Screening for Major Depressive Disorder: Analysis of Psychiatric Outpatient Data. Psychiatry Investigation, 2019, 16, 300-305.	0.7	151
57	The associations of TAC1 gene polymorphisms with major depressive disorder. Molecular and Cellular Toxicology, 2019, 15, 129-136.	0.8	1
58	Plasma ATG5 is increased in Alzheimer's disease. Scientific Reports, 2019, 9, 4741.	1.6	21
59	Relationships between hand-grip strength, socioeconomic status, and depressive symptoms in community-dwelling older adults. Journal of Affective Disorders, 2019, 252, 263-270.	2.0	43
60	How to approach to suicide prevention. Journal of the Korean Medical Association, 2019, 62, 79.	0.1	5
61	Hippocampal subfield volumes in major depressive disorder and bipolar disorder. European Psychiatry, 2019, 57, 70-77.	0.1	49
62	Whole-exome sequencing identifies variants associated with structural MRI markers in patients with bipolar disorders. Journal of Affective Disorders, 2019, 249, 159-168.	2.0	19
63	Association of metabolic syndrome and its components with suicidal ideation and depression in adults: A nationally representative sample of the Korean population. Journal of Affective Disorders, 2019, 249, 319-326.	2.0	10
64	Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression. Journal of Affective Disorders, 2019, 249, 410-417.	2.0	12
65	Intimate partner violence and incidence of depression in married women: A longitudinal study of a nationally representative sample. Journal of Affective Disorders, 2019, 245, 305-311.	2.0	11
66	Social support moderates association between posttraumatic growth and trauma-related psychopathologies among victims of the Sewol Ferry Disaster. Psychiatry Research, 2019, 272, 507-514.	1.7	21
67	Promising neural diagnostic biomarkers and predictors of treatment outcomes for psychiatric disorders: Novel neuroimaging approaches. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 91, 1-3.	2.5	3
68	Differentiating between bipolar and unipolar depression in functional and structural MRI studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 91, 20-27.	2.5	144
69	Interactive effects of genetic polymorphisms and childhood adversity on brain morphologic changes in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 91, 4-13.	2.5	37
70	Big Data and Discovery Sciences in Psychiatry. Advances in Experimental Medicine and Biology, 2019, 1192, 3-15.	0.8	3
71	The Development of Evidence-Based Guideline for Diagnosis and Management of Headache in Korea. Psychiatry Investigation, 2019, 16, 199-205.	0.7	3
72	Comorbid Zolpidem Dependence and Over-the-Counter Compound Analgesic Abuse. Clinical Psychopharmacology and Neuroscience, 2019, 17, 323-325.	0.9	5

#	Article	IF	Citations
73	Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for <i>CACNA1C, CHRNA7</i> and <i>MAPK1</i> . Clinical Psychopharmacology and Neuroscience, 2019, 17, 364-368.	0.9	12
74	The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study. Clinical Psychopharmacology and Neuroscience, 2019, 17, 495-502.	0.9	12
75	Diagnostic and Therapeutic Model for Korean Major Depressive Disorder Using Multi-Modal Data. Journal of KIISE, 2019, 46, 71-76.	0.0	0
76	Comparison of Morning and Evening/Night Dosing on the Efficacy of Escitalopram in Major Depressive Disorder at Naturalistic Setting. Chronobiology in Medicine, 2019, 1, 152-156.	0.2	0
77	The effects of 5-HTTLPR and BDNF Val66Met polymorphisms on neurostructural changes in major depressive disorder. Psychiatry Research - Neuroimaging, 2018, 273, 25-34.	0.9	35
78	Social capital, socioeconomic status, and depression in community-living elderly. Journal of Psychiatric Research, 2018, 98, 133-140.	1.5	68
79	Hot Genes in Schizophrenia: How Clinical Datasets Could Help to Refine their Role. Journal of Molecular Neuroscience, 2018, 64, 273-286.	1.1	5
80	Tinnitus, depression, and suicidal ideation in adults: A nationally representative general population sample. Journal of Psychiatric Research, 2018, 98, 124-132.	1.5	34
81	Efficacy of antidepressants: bias in randomized clinical trials and related issues. Expert Review of Clinical Pharmacology, 2018, 11, 15-25.	1.3	16
82	Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features. Journal of Molecular Neuroscience, 2018, 64, 62-74.	1.1	3
83	Sickness absence indicating depressive symptoms of working population in South Korea. Journal of Affective Disorders, 2018, 227, 443-449.	2.0	2
84	Interaction effects of oxytocin receptor gene polymorphism and depression on hippocampal volume. Psychiatry Research - Neuroimaging, 2018, 282, 18-23.	0.9	19
85	Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample. Advances in Therapy, 2018, 35, 1656-1670.	1.3	14
86	Emotional labor and depressive mood in service and sales workers: Interactions with gender and job autonomy. Psychiatry Research, 2018, 267, 490-498.	1.7	25
87	Current Clinical Applications of Diffusion-Tensor Imaging in Neurological Disorders. Journal of		

#	Article	IF	Citations
91	A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. Clinical Psychopharmacology and Neuroscience, 2018, 16, 469-480.	0.9	35
92	A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. Clinical Psychopharmacology and Neuroscience, 2018, 16, 469-480.	0.9	1
93	The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder. Advances in Therapy, 2017, 34, 713-724.	1.3	15
94	Influence of FKBP5 polymorphism and DNA methylation on structural changes of the brain in major depressive disorder. Scientific Reports, 2017, 7, 42621.	1.6	74
95	Vesicular monoamine transporter 1 gene polymorphism and white matter integrity in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 77, 138-145.	2.5	13
96	Precarious employment associated with depressive symptoms and suicidal ideation in adult wage workers. Journal of Affective Disorders, 2017, 218, 201-209.	2.0	52
97	Investigational dopamine antagonists for the treatment of schizophrenia. Expert Opinion on Investigational Drugs, 2017, 26, 687-698.	1.9	18
98	Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. Advances in Therapy, 2017, 34, 1482-1497.	1.3	3
99	Increase in the prescription rate of antidepressants after the Sewol Ferry disaster in Ansan, South Korea. Journal of Affective Disorders, 2017, 219, 31-36.	2.0	16
100	TESC gene-regulating genetic variant (rs7294919) affects hippocampal subfield volumes and parahippocampal cingulum white matter integrity in major depressive disorder. Journal of Psychiatric Research, 2017, 93, 20-29.	1.5	42
101	Cognitive performance norms from the Korean genome and epidemiology study (KoGES). International Psychogeriatrics, 2017, 29, 1909-1924.	0.6	5
102	Depression and Cognitive Function in Mild Cognitive Impairment: A 1-Year Follow-Up Study. Journal of Geriatric Psychiatry and Neurology, 2017, 30, 280-288.	1.2	16
103	The association between substance P and white matter integrity in medication-naive patients with major depressive disorder. Scientific Reports, 2017, 7, 9707.	1.6	11
104	Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis. Journal of Psychiatric Research, 2017, 84, 292-300.	1.5	37
105	Local gyrification index in patients with major depressive disorder and its association with tryptophan hydroxylaseâ€2 (<scp><i>TPH2</i></scp>) polymorphism. Human Brain Mapping, 2017, 38, 1299-1310.	1.9	35
106	Alterations in the brainstem volume of patients with major depressive disorder and their relationship with antidepressant treatment. Journal of Affective Disorders, 2017, 208, 68-75.	2.0	13
107	Measurement-based Treatment of Residual Symptoms Using Clinically Useful Depression Outcome Scale: Korean Validation Study. Clinical Psychopharmacology and Neuroscience, 2017, 15, 28-34.	0.9	15
108	Eye Movement Desensitization and Reprocessing to Facilitate Posttraumatic Growth: A Prospective Clinical Pilot Study on Ferry Disaster Survivors. Clinical Psychopharmacology and Neuroscience, 2017, 15, 320-327.	0.9	8

#	Article	IF	CITATIONS
109	Prevalence and Associated Factors of Depression in General Population of Korea: Results from the Korea National Health and Nutrition Examination Survey, 2014. Journal of Korean Medical Science, 2017, 32, 1861.	1.1	101
110	A Korean validation study of the Clinically Useful Anxiety Outcome Scale: Comorbidity and differentiation of anxiety and depressive disorders. PLoS ONE, 2017, 12, e0179247.	1.1	10
111	Assessing reporting quality of randomized controlled trial abstracts in psychiatry: Adherence to CONSORT for abstracts: A systematic review. PLoS ONE, 2017, 12, e0187807.	1.1	28
112	PS227. Psychometric Properties of the Korean Version of the Clinically Useful Depression Outcome Scale (CUDOS) in Psychiatric Outpatients. International Journal of Neuropsychopharmacology, 2016, 19, 83-83.	1.0	0
113	Perspectives on the Happiness of Community-Dwelling Elderly in Korea. Psychiatry Investigation, 2016, 13, 50.	0.7	20
114	Vilazodone for the Treatment of Depression: An Update. Chonnam Medical Journal, 2016, 52, 91.	0.5	34
115	Effects of a Polymorphism of the Neuronal Amino Acid Transporter SLC6A15 Gene on Structural Integrity of White Matter Tracts in Major Depressive Disorder. PLoS ONE, 2016, 11, e0164301.	1.1	42
116	Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update. Chonnam Medical Journal, 2016, 52, 159.	0.5	48
117	PM449. Hot genes in schizophrenia: case-control, pharmacogenetics and exploratory analyses in two independent samples. International Journal of Neuropsychopharmacology, 2016, 19, 63-63.	1.0	0
118	Influence of Bcl I C/G (rs41423247) on hippocampal shape and white matter integrity of the parahippocampal cingulum in major depressive disorder. Psychoneuroendocrinology, 2016, 72, 147-155.	1.3	15
119	Computational metaâ€nnalysis of statistical parametric maps in major depression. Human Brain Mapping, 2016, 37, 1393-1404.	1.9	158
120	Precision medicine for psychopharmacology: a general introduction. Expert Review of Neurotherapeutics, 2016, 16, 831-839.	1.4	15
121	Brain-derived neurotrophic factor promoter methylation and cortical thickness in recurrent major depressive disorder. Scientific Reports, 2016, 6, 21089.	1.6	71
122	Association between reduced white matter integrity in the corpus callosum and serotonin transporter gene DNA methylation in medication-naive patients with major depressive disorder. Translational Psychiatry, 2016, 6, e866-e866.	2.4	80
123	Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway. BMC Psychiatry, 2016, 16, 106.	1.1	24
124	Hippocampal subfield analysis in medication-naÃ-ve female patients with major depressive disorder. Journal of Affective Disorders, 2016, 194, 21-29.	2.0	54
125	Mental health service use in adults with suicidal ideation within a nationally representative sample of the Korean population. Journal of Affective Disorders, 2016, 193, 339-347.	2.0	19
126	Imaging genetics studies on monoaminergic genes in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 311-319.	2.5	37

#	Article	IF	CITATIONS
127	Sleep Irregularity in the Previous Week Influences the First-Night Effect in Polysomnographic Studies. Psychiatry Investigation, 2016, 13, 203.	0.7	9
128	Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice. Chonnam Medical Journal, 2015, 51, 66.	0.5	16
129	Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action. Psychiatry Investigation, 2015, 12, 155.	0.7	26
130	Posttraumatic Growth and Resilience: Assessment and Clinical Implications. Journal of Korean Neuropsychiatric Association, 2015, 54, 32.	0.2	11
131	Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study. Journal of Psychiatric Research, 2015, 66-67, 84-94.	1.5	30
132	The impact of 3D and 2D TV watching on neurophysiological responses and cognitive functioning in adults. European Journal of Public Health, 2015, 25, 1047-1052.	0.1	7
133	Association analysis for corticotropin releasing hormone polymorphisms with the risk of major depressive disorder and the response to antidepressants. Behavioural Brain Research, 2015, 292, 116-124.	1.2	21
134	Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. Journal of Psychiatry and Neuroscience, 2015, 40, 174-186.	1.4	53
135	The Influence of AHI1 Variants on the Diagnosis and Treatment Outcome in Schizophrenia. International Journal of Molecular Sciences, 2015, 16, 2517-2529.	1.8	11
136	Pain and Depression: A Neurobiological Perspective of Their Relationship. Psychiatry Investigation, 2015, 12, 1.	0.7	77
137	Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: A systematic review and meta-analysis. Journal of Psychiatric Research, 2015, 64, 88-98.	1.5	47
138	Association of brain-derived neurotrophic factor DNA methylation and reduced white matter integrity in the anterior corona radiata in major depression. Journal of Affective Disorders, 2015, 172, 74-80.	2.0	92
139	Development of an International Schedule for the Assessment and Staging of Care for Dementia. Journal of Alzheimer's Disease, 2015, 44, 139-151.	1.2	9
140	Outpatient Follow-Up Visit after Hospital Discharge Lowers Risk of Rehospitalization in Patients with Schizophrenia: A Nationwide Population-Based Study. Psychiatry Investigation, 2015, 12, 425.	0.7	23
141	Psychiatric Symptoms in a Patient with Influenza A (H1N1) Treated with Oseltamivir (Tamiflu): A Case Report. Clinical Psychopharmacology and Neuroscience, 2015, 13, 209-211.	0.9	13
142	Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection. Neuropsychiatric Disease and Treatment, 2014, 10, 1605.	1.0	8
143	Evidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition. Journal of Korean Medical Science, 2014, 29, 468.	1.1	13
144	Impact of lingual gyrus volume on antidepressant response and neurocognitive functions in Major Depressive Disorder: A voxel-based morphometry study. Journal of Affective Disorders, 2014, 169, 179-187.	2.0	99

#	Article	IF	CITATIONS
145	A review of current evidence for acetyl-l-carnitine in the treatment of depression. Journal of Psychiatric Research, 2014, 53, 30-37.	1.5	80
146	Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: A multi-center, naturalistic study. Journal of Psychiatric Research, 2014, 49, 75-82.	1.5	20
147	Usefulness of the Patient Health Questionnaire-9 for Korean Medical Students. Academic Psychiatry, 2014, 38, 661-667.	0.4	28
148	Cortical thickness, cortical and subcortical volume, and white matter integrity in patients with their first episode of major depression. Journal of Affective Disorders, 2014, 155, 42-48.	2.0	93
149	The potential role of atypical antipsychotics for the treatment of posttraumatic stress disorder. Journal of Psychiatric Research, 2014, 56, 72-81.	1.5	27
150	Association between Glucocorticoid Receptor Methylation and Hippocampal Subfields in Major Depressive Disorder. PLoS ONE, 2014, 9, e85425.	1.1	125
151	A Meta-Analysis Comparing Open-Label versus Placebo-Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and Promises. Psychiatry Investigation, 2014, 11, 371.	0.7	9
152	Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder. Psychiatry Investigation, 2014, 11, 481.	0.7	13
153	Epistatic Interactions between CREB and CREM Variants in Affective Disorder. Psychiatry Investigation, 2014, 11, 200.	0.7	2
154	The relationship between somatic symptoms and depression. Neuroendocrinology Letters, 2014, 35, 463-9.	0.2	9
155	Do We Need to Consider Ethno-cultural Variation in the Use of Atypical Antipsychotics for Asian Patients with Major Depressive Disorder?. CNS Drugs, 2013, 27, 47-51.	2.7	16
156	Management of Chronic Depressive Patients with Residual Symptoms. CNS Drugs, 2013, 27, 53-57.	2.7	12
157	Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Review of Neurotherapeutics, 2013, 13, 851-870.	1.4	83
158	Effect of the COMT vall58met polymorphism on white matter connectivity in patients with major depressive disorder. Neuroscience Letters, 2013, 545, 35-39.	1.0	68
159	Uptake of Web-Based Clinical Resources from the MacArthur Initiative on Depression and Primary Care. Community Mental Health Journal, 2013, 49, 166-171.	1.1	13
160	Dilemma for enhancing psychiatrists' adherence to guideline (evidence)-based practice. Expert Review of Neurotherapeutics, 2013, 13, 751-754.	1.4	3
161	Oral scopolamine augmentation for major depression. Expert Review of Neurotherapeutics, 2013, 13, 19-21.	1.4	4
162	Diagnosis and treatment of dementia in primary care. Journal of the Korean Medical Association, 2013, 56, 1104.	0.1	15

#	Article	IF	Citations
163	Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (I): Initial Choice of Antidepressant Treatment. Journal of Korean Neuropsychiatric Association, 2013, 52, 253.	0.2	4
164	Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (III): Dose Increment, Switching, Combination, and Augmentation Strategy in Antidepressant Therapy. Journal of Korean Neuropsychiatric Association, 2013, 52, 386.	0.2	2
165	CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression. Psychiatry Investigation, 2013, 10, 286.	0.7	16
166	Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (II): Antidepressant Efficacy Compared with Placebo, Difference in Efficacy of Antidepressants, and Appropriate Time of Efficacy Judgment in Antidepressant Therapy. Journal of Korean Neuropsychiatric Association, 2013, 52, 372.	0.2	2
167	Can botulinum toxin improve mood in depressed patients?. Expert Review of Neurotherapeutics, 2012, 12, 1049-1051.	1.4	10
168	Association of chronic divalproex sodium use and brain atrophy in Alzheimer's disease. Expert Review of Neurotherapeutics, 2012, 12, 155-158.	1.4	0
169	Impact of tryptophan hydroxylase 2 G-703T polymorphism on anger-related personality traits and orbitofrontal cortex. Behavioural Brain Research, 2012, 231, 105-110.	1.2	20
170	Association between Serotonin Transporter-Linked Polymorphic Region and Escitalopram Antidepressant Treatment Response in Korean Patients with Major Depressive Disorder. Neuropsychobiology, 2012, 66, 221-229.	0.9	19
171	Standardization of the Korean Version of the Posttraumatic Embitterment Disorder Self-Rating Scale. Psychiatry Investigation, 2012, 9, 368.	0.7	23
172	Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Psychiatry Research, 2011, 189, 26-32.	1.7	42
173	Depression, suicide, and Korean society. Journal of the Korean Medical Association, 2011, 54, 358.	0.1	13
174	Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial. Acta Neuropsychiatrica, 2011, 23, 179-183.	1.0	8
175	Demonstration of decreased gray matter concentration in the midbrain encompassing the dorsal raphe nucleus and the limbic subcortical regions in major depressive disorder: An optimized voxel-based morphometry study. Journal of Affective Disorders, 2011, 133, 128-136.	2.0	92
176	Study design and methods of the Ansan Geriatric Study (AGE study). BMC Neurology, 2009, 9, 10.	0.8	35
177	Venlafaxine versus Mirtazapine in the??Treatment of Undifferentiated Somatoform Disorder. Clinical Drug Investigation, 2008, 28, 251-261.	1.1	21
178	Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: A randomized, open-label, 12-week, parallel-group trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 437-444.	2.5	14
179	Validation of the Patient Health Questionnaire-9 Korean version in the elderly population: the Ansan Geriatric study. Comprehensive Psychiatry, 2008, 49, 218-223.	1.5	344
180	Paroxetine for patients with undifferentiated somatoform disorder: A prospective, open-label, 8-week pilot study. Current Therapeutic Research, 2008, 69, 221-231.	0.5	0

#	Article	IF	CITATIONS
181	Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1219-1223.	2.5	27
182	Plasma Homocysteine Is Associated with the Risk of Mild Cognitive Impairment in an Elderly Korean Population ,. Journal of Nutrition, 2007, 137, 2093-2097.	1.3	58
183	Usefulness of Beck Depression Inventory (BDI) in the Korean elderly population. International Journal of Geriatric Psychiatry, 2007, 22, 218-223.	1.3	122
184	Possible association between G-protein \hat{I}^2 3 subunit C825T polymorphism and antipsychotic-induced restless legs syndrome in schizophrenia. Acta Neuropsychiatrica, 2007, 19, 351-356.	1.0	12
185	Geriatric mental health system for the management of geriatric depression and dementia in Korea. Psychiatria Et Neurologia Japonica - Seishin Shinkeigaku Zasshi, 2006, 108, 1176-7.	0.1	0